Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to assess the efficacy of rozanolixizumab as measured by seizure freedom, change in cognitive function, use of rescue medication, onset of seizure freedom and to assess safety and tolerability.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04875975
Study type Interventional
Source UCB Pharma
Contact
Status Terminated
Phase Phase 2
Start date September 27, 2021
Completion date April 26, 2024